The purpose of this study was to evaluate the effects of population size, number of samples per individual, and level of interindividual variability (IIV) on the accuracy and precision of pharmacodynamic (PD) parameter estimates. Response data were simulated from concentration input data for an inhibitory sigmoid drug efficacy (E max ) model using Nonlinear Mixed Effect Modeling, version 5 (NONMEM). Seven designs were investigated using different concentration sampling windows ranging from 0 to 3 EC 50 (EC 50 is the drug concentration at 50% of the E max ) units. The response data were used to estimate the PD and variability parameters in NONMEM. The accuracy and precision of parameter estimates after 100 replications were assessed using the mean and SD of percent prediction error, respectively. Four samples per individual were sufficient to provide accurate and precise estimate of almost all of the PD and variability parameters, with 100 individuals and IIV of 30%. Reduction of sample size resulted in imprecise estimates of the variability parameters; however, the PD parameter estimates were still precise. At 45% IIV, designs with 5 samples per individual behaved better than those designs with 4 samples per individual. For a moderately variable drug with a high Hill coefficient, sampling from the 0.1 to 1, 1 to 2, 2 to 2.5, and 2.5 to 3 EC 50 window is sufficient to estimate the parameters reliably in a PD study.
INTRODUCTION
Population pharmacodynamic (PD) modeling is useful in assessing the quantitative relationships among dose, drug response, patient covariates, and variability. The population PD approach can be used to estimate population parameters in clinical trials, and the results can be used to optimize clinical drug development. In pharmacokinetics (PK) and PD, population analysis is useful in modeling sparse data, such as those that arise from clinical trials, where few samples (typically 1 to 3) are randomly obtained from a large number (typically a few hundred) of individuals. Therefore, sparse sampling designs should be sufficiently robust to reliably capture the parameters, as well as the variability of the parameters, of the biological system under investigation.
The purpose of this work was to evaluate, by computer simulations, sparse sampling designs that would yield reliable estimates of PD parameters of a sigmoid E max model. The specific objectives were as follows: (1) to identify a design that could provide unbiased and precise estimates of the PD and variability parameters, (2) to study the effect of sample size on the accuracy and precision of parameter estimates, and (3) to investigate the effect of interindividual variability (IIV) on the accuracy and precision of parameter estimates. Generalized development of sparse sampling designs, based on observational, as well as theoretical considerations, would allow its application to developmental candidates that conform to the considerations.
MATERIALS AND METHODS

PD Model
An inhibitory sigmoid E max model (Equation 1) was used in the evaluations. The parameters of this model were based on theophylline-induced eosinopenia. 1 The parameter estimates are: E 0 5 183/mL, E max 5 37/mL, EC 50 5 5.06 mg/L, and g 5 6.22.
where E is the drug response, E 0 is the baseline response, E max is the drug efficacy, C is the drug concentration in plasma, EC 50 is the drug concentration at 50% of the E max , and g is the sigmoidicity constant.
Statistical Model
An exponential model was used to describe the IIV in all of the PD parameters as follows:
where u i is the estimate for a PD parameter in the iÕth individual, u m represents the population mean value of this parameter, and hu i is a normally distributed random variable with an average value of 0 and variance of v. 2 The variability parameters v EC50 , v Emax , v E0 , and vg were associated with the PD parameters EC 50 , E max , E 0 , and g, respectively.
Intraindividual variability (residual error) was also described by an exponential error model as follows:
where E ij is the observed effect for the iÕth individual at time j, E mij is the model-predicted effect for the iÕth individual at time j, and e ij is the residual error that represents the difference between the observed response and the model predicted response. e ij is a normally distributed random variable with an average value of 0 and variance of s.
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The coefficient of variation of the IIV was initially set at 30% for all of the PD parameters. The coefficient of variation of the residual error was set at a moderate variability level of 25%. 2 
Simulation of Effect-Concentration Profiles
Using the PD model (Equation 1) and the theophylline parameters described above, effect-concentration profiles were simulated in nonlinear mixed effect modeling, version 5 (NONMEM), 3 taking variability into consideration. A PRED subroutine 3 was used for the simulations.
Sparse Sampling Designs
As outlined in Figure 1 , 7 sampling designs (Table 1) , each with different sampling windows (based on EC 50 concentration unit), were evaluated. Five designs had 4 samples per individual, whereas the other two designs had 5 samples per individual, for a total of 100 individuals per design. The designs were based on EC 50 units rather than ÔÔrawÕÕ plasma concentrations to facilitate the extrapolation of the results of this evaluation to a general case for a drug with a large g value. For each design, 4 or 5 random concentration points from within the appropriate sampling windows were generated for each individual in Excel (using 
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the random function). The corresponding response data were then simulated using NONMEM. For each scenario, 100 data sets were replicated. Thus, the evaluation of any particular design was based on 40,000 or 50,000 responseconcentration ÔÔobservationsÕÕ (ie, 4 samples 3 100 subjects 3 100 replications or 5 samples 3 100 subjects 3 100 replications).
Effect of Sample Size
The effect of sample size on the accuracy and precision of parameter estimates was evaluated for designs 1, 4, and 6 with 25 and 50 ÔÔindividuals.ÕÕ
Effect of IIV
IIV in PD parameters was set at 30% for each of the 7 designs. Furthermore, to evaluate the effect of variability, designs 1, 4, and 6 were also assessed at a 45% level of IIV.
Parameter Estimation
For each simulated data set, PD parameters (EC 50 , E max , E 0 , and g) and variability parameters were estimated in NONMEM using the first-order conditional estimation method (FOCE). This method requires more computer time to perform an analysis than with the first-order method (FO), especially with large data sets and/or complex structural models, and it has been found to provide more accurate and precise estimates of the variability parameters.
3,4
Bias and Precision of Parameter Estimates
The accuracy and precision of the estimates from each data set were evaluated using the percent prediction error (%PE) as follows:
where u sim is the estimated population value of the parameter from any single simulated data set, and u true is the true population value for the parameter. The %PE was calculated for the 100 simulated data sets in each scenario. The mean and SD of %PE were used to measure the bias and precision of parameter estimates, respectively. A mean of %PE for a parameter estimate 15% was accepted as being unbiased. 5 A SD of %PE for a parameter estimate 35% was accepted as being precise. 5 
RESULTS
PD Parameters
Bias and precision of parameter estimates were used to judge the performance of the designs that were evaluated. All of the designs gave unbiased estimates of all of the PD parameters (EC 50 , E max , E 0 , and g) except for design 2 and design 5, which gave a marginally biased estimate of g ( Figure 2 ). All 7 of the designs gave precise estimates of all of the PD parameters ( Figure 3 ).
Variability Parameters
All of the 7 designs gave unbiased estimates of v EC50 , v Emax (except design 1, which gave a marginally biased estimate of v Emax ), and v E0 and biased estimates of vg (except design 2 and design 4, which gave an unbiased estimate of vg). All of the designs gave precise estimates of v EC50 and v E0 and an imprecise estimate of vg. All of the designs except designs 1, 2, and 3, gave precise estimates of v Emax . The estimate of the residual error (s) was unbiased and precise for all of the 7 designs.
From the 7 designs initially studied, design 4, with only 4 samples per individual, was found to be a satisfactory design where a concentration up to 3 EC 50 units can be Figure 3 . Precision of parameter estimates using the 7 investigated designs. The horizontal line represents the 35% cutoff.
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achieved for a moderately variable drug (IIV 5 30%). This design provides an unbiased and precise estimate of all of the PD and variability parameters with the exception of the vg estimate, which was unbiased but imprecise. Design 4 could be modified to include a baseline measurement (at time 0), which then becomes design 5. This design gave estimates of PD parameters that were similar in terms of bias and precision to design 4, with the exception of g and vg estimates, which were biased with design 5. Design 1 could be used instead of design 4 in cases where a concentration of 3 EC 50 units cannot be achieved (eg, when toxicity is encountered at high concentrations), but v Emax would be biased and imprecise. Consequently, designs 1 and 4, with 4 samples per individual, as well as design 6, with 5 samples per individual, were selected to additionally study the effect of sample size and increasing level of IIV on the accuracy and precision of parameter estimates.
Effect of Sample Size
The effect of sample size on parameter estimates was evaluated using populations of 25, 50, and 100 individuals. 
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mates of all of the variability parameters but not the residual error in designs 1, 4 and 6.
Effect of IIV
Increasing IIV from 30% to 45% using design 1 did not affect the accuracy and precision of any of the parameters except g, which was biased (Figures 6 and 7) . With design 4, increasing the level of IIV resulted in biased estimates of g, v EC50 , and vg. With design 6, the accuracy and precision of parameter estimates were not affected by increasing the level of IIV. Thus, design 6 was chosen to be the best design for a highly variable drug. The estimate of the residual error was still accurate and precise at the 45% level of IIV.
DISCUSSION
Simulation is a valuable tool to investigate different design issues before the execution of a clinical trial and is useful for selecting a particular design that may best meet the objective of a study. Sparse sampling designs can be useful in large populations (eg, clinical trials) in which intensive sampling is not practical. 6 In this study, the ability of several hypothetical sparse sampling designs to provide accurate and precise estimates of PD parameters was investigated by simulating drug response data from concentration inputs using the inhibitory sigmoid E max model. It is appropriate to simulate response data directly from concentration input (and not time input), because the PD model describes the concentration-effect relationship; time is not an explicit variable in the relationship. Seven designs, which differed regarding their ÔÔcoverageÕÕ of the concentration-response profile, were evaluated. Design 1 had concentration samples up to 2 EC 50 units; however, designs 2 through 7 had concentration samples up to 3 EC 50 units. Design 1 gave imprecise and marginally biased estimates of v Emax . To estimate v Emax reliably, values at the higher end of the concentration-response range are needed. Designs 2 and 3 gave accurate but marginally imprecise estimate of v Emax , and designs 4 and 5 gave accurate and precise estimates to v Emax . This is attributable to the importance of the 2 to 3 EC 50 sampling window in estimating the variability parameter in E max . Overall, these results show that at least 2 samples are needed from the 2 to 3 EC 50 region to get an accurate and precise estimate of v Emax . This is consistent with a similar finding by Girgis and Rosenbaum, 7 where 3 samples per subject design were studied. It was found that at the 30% level of IIV, a design with 0.1 to 0.5, 0.5 to 1, and 1 to 3 EC 50 units gave precise estimates of all of the PD parameters but imprecise estimate of v Emax . Sampling windows have been successfully applied in the past, 4 and are practical from an implementation standpoint, whereas in clinical trials it is not possible to sample individuals at fixed time points. In this simulation work, we have shown how sampling windows can be optimized for PD parameter estimation from sparse sampling. Parameter estimates obtained from the different designs were evaluated in terms of bias and precision. It has been shown that estimates of bias and precision give better descriptions of predictive performance than correlation coefficients and/or the regression of predictions with true value. 8 For designs 1, 4, and 6, increasing the sample size from 25 to 100 individuals improved the precision of variability parameter estimates. The accuracy of variability parameter estimates was slightly affected by increasing the sample size. PD parameter estimates in terms of accuracy and precision were not affected by the sample size.
Design 6 gave accurate and precise estimates of all of the PD and variability parameters with the exception of vg, at 30% and 45% levels of IIV. Thus, it was chosen to be the best design for a highly variable drug.
In general, we found that the PK/PD parameters are estimated more accurately than the variability parameters. Al-Banna et al 9 and Ette et al l0 also found that the population PK fixed-effect parameters were reliably estimated, but the IIV parameters were inaccurate for most of the sampling schemes. Sun et al 5 and White et al 2 found that there was an increase in bias and an imprecision in PK parameter estimation as intersubject variability was increased.
In summary, this evaluation illustrated how parameter estimates are influenced by study design in which the underlying data are sparse. Computer simulations showed that a sparse sampling design in which concentration samples taken from the 0.1 to 1, 1 to 2, 2 to 2.5, and 2.5 to 3 EC 50 windows performed best at moderate level of IIV (30% IIV) for a drug with a high Hill coefficient. At a higher level of IIV (45%), design 6 (0.1 to 0.5, 0.5 to 1, 1 to 1.5, 1.5 to 2, and 2 to 3 EC 50 units) was found to perform well. Work is in progress to evaluate how similar designs can be applied to drugs with low Hill coefficients. Overall, this generalization can help PK/PD evaluations in clinical trials.
